Nobel Prize 2026 'Optogenetics' Pioneer Karl Deisseroth and Two Others Selected for Nobel Prize in Physiology or Medicine

This year's Nobel Prize in Physiology or Medicine has been awarded to three scientists who pioneered the field of 'optogenetics,' a technology that uses light to precisely control the activity of nerve cells. Their research is recognized as an innovative achievement that transcends basic science and transforms the paradigm of medicine, including the treatment of brain diseases and restoration of vision.

The Nobel Committee at Sweden's Karolinska Institute announced on December 5 (local time) that the 2026 Nobel Prize in Physiology or Medicine recipients are Karl Deisseroth, professor at Stanford University in the United States, Peter Hegemann, professor at Humboldt University in Germany, and Georg Nagel, professor at the University of Würzburg in Germany.

'Technology of Light' Opening New Horizons in Neuroscience

Optogenetics is a compound term of 'opto' (light) and 'genetics.' It is a cutting-edge technology that uses genetic engineering to express light-responsive proteins (such as channelrhodopsin) in specific nerve cells, and then uses light to turn the activity of those nerve cells on or off.

Past brain research was limited to stimulating the entire brain through drugs or electrical stimulation, making it difficult to precisely understand the function of specific neural circuits. However, thanks to the pioneering research of these laureates, scientists can now control the operation of specific brain neural circuits on a millisecond scale and observe behavioral changes.

From Parkinson's Disease to Vision Restoration…Commercialization Accelerates

The Nobel Committee stated that their research made decisive contributions to decoding the complex neural circuit maps of the brain. Currently, optogenetics is being actively applied not only in developing treatments for brain diseases requiring precise neural regulation, such as Parkinson's disease, depression, and schizophrenia, but also in research on gene and optical therapies that partially restore vision in patients who have lost sight due to retinal degeneration.

The academic community anticipates that this award will accelerate the development of treatments for intractable diseases based on optogenetics and convergent research with brain-computer interface (BCI) technology.